CA2084136A1 - Conception, construction et expression de proteines chimeriques pour la mise au point de vaccins et de reactifs diagnostiques
- Google Patents
Conception, construction et expression de proteines chimeriques pour la mise au point de vaccins et de reactifs diagnostiques
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Green Cross Vaccine Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Publication of CA2084136A1publicationCriticalpatent/CA2084136A1/fr
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
CA002084136A1992-06-171993-01-21Conception, construction et expression de proteines chimeriques pour la mise au point de vaccins et de reactifs diagnostiques
AbandonedCA2084136A1
(fr)
Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV
Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis
High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A
Assembly-defective point mutants of the human immunodeficiency virus type 1 Gag precursor phenotypically expressed in recombinant baculovirus-infected cells
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway
Proteines du parvovirus b19 humain et particules d'aspect viral, leur production et leur utilisation dans les analyses diagnostiques et les vaccins